Background -The aim of this study was to report the effects ofa three-drug chemotherapy regimen in patients with symptomatic AIDS-related pulmonary Kaposi's sarcoma and to analyse prognostic factors for survival. Methods -Thirty consecutive HIV seropositive patients with respiratory symptoms and proven pulmonary Kaposi's sarcoma were treated with the same therapeutic regimen comprising adriamycin (30 mglm2), bleomycin (10 mg/m2), and vincristine (2 mg) administered intravenously once every four weeks. Results -Two patients died during the first course of chemotherapy. In the other 28 cases dyspnoea improved and Pao2 rose despite minimal (n = 17) or no (n = 11) improvement in the chest radiographic appearance. The median survival from the beginning of chemotherapy was 6 5 months. Poor prognostic factors for survival were: (1) absence of cutaneous Kaposi's sarcoma; (2) previous opportunistic infection; (3) CD4 cell count <100/tll; (4) leucocytes <3500/tt1; (5) haemoglobin <10 g/dl; and (6) 
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COMPLICATIONS
Fever related to bleomycin administration was observed in three patients which was subChemotherapy in pulmonary Kaposi's sarcoma Table 1 Characteristics ofpatients (n = 30) and pretreatment laboratory findings sequently prevented by paracetamol. Two cases of peripheral neuropathy and one of clinically asymptomatic cardiomyopathy were observed, related in part to treatment with vincristine and adriamycin. None of the side effects had any influence on the administration of the chemotherapy. By contrast, haematological toxicity (neutropenia: grade 2-3 (n = 19), grade 4 (n = 5), and thrombopenia: grade 2 (n = 9)) lengthened the chemotherapy intercycle period from four weeks to 5-6 weeks (range 4-9).
Fever (>38 5°C for more than 48 hours) was observed in 16 ofthe 28 patients. An associated opportunistic infection occurred in five patients at the time of diagnosis of pulmonary Kaposi's sarcoma: cytomegalovirus retinitis (n = 3), Pneumocystis carinii pneumonia (n = 1), cerebral toxoplasmosis (n = 1). Opportunistic infections occurred during follow up in 10 of the 28 patients.
Discussion
The overall survival of patients with visceral involvement by Kaposi 
